STK11 and endometrial carcinoma: Rapamycin as a single agent has been shown to potently inhibit the growth and viability of endometrial carcinomas, oviductal neoplasias and papillary bladder tumours in Lkb1−/− and Lkb1−/−;Pten−/− GEMMs (Contreras et al, 2010; Shorning et al, 2011; Tanwar et al, 2012), as well as reduce the number and confluence of melanocytic lesions in BrafV600E; LKB1−/− mice (Damsky et al, 2015), however, rapamycin failed to induce a therapeutic response in lung tumours from KrasG12D-driven LKB1-deficient GEMMs (Liang et al, 2010).